Polar Capital Holdings Plc

Position in TSHA — Taysha Gene Therapies, Inc.

CIK 1837309 London, X0

Position in TSHA

as of Mar 31, 2026 · filed May 15, 2026 Compact

Position Value

$25,274,899

-$18,347,817 QoQ

Shares Held

5,654,340

-28.7% QoQ

Ownership

1.97%

of shares outstanding

% of Portfolio

0.11%

of 13F equity value

Holder Rank

—

not a current holder

Holding Since

Sep 2023

11 quarters on record

Voting authority Sole 100.ToString("F0")% Shared 0.ToString("F0")% None 0.ToString("F0")%

Healthcare · as of Mar 31, 2026

Polar Capital Holdings Plc holds $3,129,351,296 across 43 Biotechnology names. TSHA ranks #32 (0.8% of the industry book) .

#	Ticker	Company	Shares	Value (USD)
1	XENE	Xenon Pharmaceuticals Inc.	4,405,312	$256,168,892
2	ELVN	Enliven Therapeutics, Inc.	5,065,933	$198,584,573
3	NUVL	Nuvalent, Inc.	1,831,253	$187,611,869
4	BBIO	BridgeBio Pharma, Inc.	2,519,306	$187,083,663
5	MDGL	Madrigal Pharmaceuticals, Inc.	289,310	$151,445,105
6	ASND	Ascendis Pharma A/S	651,712	$149,066,085
7	REGN	Regeneron Pharmaceuticals, Inc.	192,546	$148,768,741
8	RYTM	Rhythm Pharmaceuticals, Inc.	1,615,586	$140,507,514

11 filing rows on record

Report Date	Value (USD)	Shares	Change	Type	Discretion	Filed
2026-03-31	$25,274,899	5,654,340	-28.7%	Shares	Defined	2026-05-15
2025-12-31	$43,622,716	7,931,403	+49.8%	Shares	Defined	2026-02-17
2025-09-30	$17,310,984	5,293,879	+5.9%	Shares	Defined	2025-11-14
2025-06-30	$11,550,000	5,000,000	+66.7%	Shares	Defined	2025-08-14
2025-03-31	$4,170,000	3,000,000	0.0%	Shares	Defined	2025-05-15
2024-12-31	$5,190,000	3,000,000	-0.8%	Shares	Defined	2025-02-14
2024-09-30	$6,080,250	3,025,000	0.0%	Shares	Defined	2024-11-14
2024-06-30	$6,776,000	3,025,000	+20.1%	Shares	Defined	2024-08-14
2024-03-31	$7,229,268	2,518,909	0.0%	Shares	Defined	2024-05-15
2023-12-31	$4,458,468	2,518,909	-0.4%	Shares	Defined	2024-02-14
2023-09-30	$7,994,800	2,530,000	—	Shares	Defined	2023-11-22
No filing history on record for this holder in this stock.